STOCK TITAN
  1. Home
  2. News
  3. TFFP

Tff Pharmaceuticals Inc - TFFP STOCK NEWS

Welcome to our dedicated news page for Tff Pharmaceuticals (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on Tff Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tff Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tff Pharmaceuticals's position in the market.

News
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Rhea-AI Summary
TFF Pharmaceuticals (TFFP) announces positive data from the TFF TAC Phase 2 trial for lung transplant recipients at the ISHLT 44th Annual Meeting. The study shows that TFF TAC prevents rejection at a fraction of the oral tacrolimus dose, with lower exposure levels potentially reducing kidney toxicity. Gene expression analysis indicates normalization of rejection-related genes in patients on TFF TAC, supporting its potential as an innovative immunosuppressive therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
clinical trial
-
News
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
TFF Pharmaceuticals Reports Financial Results for Q4 and Full Year 2023; Prioritizes TFF TAC Program, Explores Alternatives for TFF VORI; Positive Clinical Data Presented
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
earnings
-
News
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
Rhea-AI Summary
TFF Pharmaceuticals, Inc. announces successful transition of all patients to TFF TAC with no acute rejection, positive data from TFF VORI program, and plans to explore strategic alternatives. The company prioritizes TFF TAC based on promising Phase 2 results, showing potential in lung transplant medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.35%
Tags
none
News
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
Rhea-AI Summary
TFF Pharmaceuticals, Inc. announces the acceptance of its late-breaking clinical science abstract for oral presentation at the 44th Annual ISHLT 2024 Meeting. The Phase 2 trial data of TFF TAC demonstrates successful transition of patients from oral tacrolimus to TFF TAC, showing promising results in immunosuppression therapy. Professor Gregory Snell highlights the potential of TFF TAC to provide innovative delivery of immunosuppression therapy with reduced systemic exposure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
clinical trial
-
News
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
TFF Pharmaceuticals, Inc. announced the closing of a registered direct offering and a private placement, raising approximately $1.2 million. The offering included 147,500 shares of common stock priced at $8.00 per share, along with unregistered warrants. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
offering
-
News
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
TFF Pharmaceuticals (TFFP) announces a registered direct offering and private placement of common stock and warrants. The Company will sell 147,500 shares at $8.00 per share, with warrants to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
offering
News
TFF Pharmaceuticals Announces Update on Clinical Programs
Rhea-AI Summary
TFF Pharmaceuticals, Inc. prioritizes the clinical development of Tacrolimus Inhalation Powder (TFF TAC) due to positive Phase 2 data, aiming to address a critical need in lung transplant medicine. The company plans to explore strategic options for TFF VORI following encouraging data. TFF Pharmaceuticals will provide clinical updates on both programs on March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
none
-
News
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (TFFP) announced that its CEO will present a corporate overview at the 36th Annual Roth Conference. The company focuses on innovative drug products using Thin Film Freezing technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences
-
News
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference 
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (TFFP) will present data from the Phase 2 trial of Voriconazole Inhalation Powder for the treatment of invasive pulmonary aspergillosis at the AAAM Conference. The presentation will be made by Dr. Zamaneh Mikhak, the Chief Medical Officer of TFF Pharmaceuticals, on January 26th, 2024, in Milan, Italy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.88%
Tags
conferences clinical trial
News
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, featuring initial data from the Company’s ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC). The study aims to prevent lung transplant rejection, addressing the high unmet medical need in lung transplantation with a 5-year mortality rate of approximately 50%. Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital, expressed optimism about the potential of TFF TAC in optimizing immunosuppression in the lung while avoiding toxicities associated with systemically administered immunosuppressive therapies. The presentation will take place in Prague, Czech Republic from April 10-13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
Stock TFFP logo
Tff Pharmaceuticals Inc

Nasdaq:TFFP

TFFP Rankings

N/A Ranked by Market Cap
#5435 Ranked by Stock Gains
N/A Ranked by Dividends

TFFP Stock Data

9.70M
2.23M
4.71%
13.87%
3.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About TFFP

tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.